Candidemia Clinical Trial
Official title:
A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Children (2-5 Years AND 6-11 Years) And Adolescents (12-16 Years) With Esophageal Candidiasis Or Other Invasive Candidiasis
Children with fungal infections will be divided into two groups by weight. Children weighing < 25 kg will receive a higher dose of study medication (per kg body weight) for 10 to 14 days than children weighing > 25 kg.
This is a prospective, multicenter, open-label, repeat-dose study conducted in two groups.
Subjects in Group 1 and Group 2 will receive treatment for 10 to 14 days (per investigator
clinical judgment); dose level (3.0 mg/kg or 4.5 mg/kg) will be determined by the subject's
weight at baseline. Study procedures in both groups will be similar except that serial blood
samples for assessment of pharmacokinetics will be collected in Group 1. Subjects may only
participate in one group of the study.
At least 24 subjects, with at least 8 in each of three age ranges, will be enrolled in Group
1 (PK + safety). At least 36 subjects will be enrolled in Group 2 (safety), with at least 12
in each of the three age ranges.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01982071 -
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
|
Phase 4 | |
| Completed |
NCT02163889 -
Serial Therapeutic and Antifungal Monitoring Protocol
|
||
| Completed |
NCT02244606 -
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
|
Phase 2 | |
| Recruiting |
NCT01438216 -
Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
|
N/A | |
| Not yet recruiting |
NCT01249313 -
Risk Factor and Outcome of Candidemia
|
N/A | |
| Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
| Terminated |
NCT01213823 -
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
|
Phase 4 | |
| Completed |
NCT00105144 -
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
|
Phase 3 | |
| Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
| Completed |
NCT03604705 -
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
|
Phase 2 | |
| Completed |
NCT00607763 -
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
| Recruiting |
NCT04147975 -
Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
|
||
| Completed |
NCT01734525 -
Negative Beta Glucan in ICU Patients
|
Phase 4 | |
| Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
| Completed |
NCT03363841 -
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
|
Phase 3 | |
| Completed |
NCT03799172 -
Echinocandins Versus Azoles for Candidemia Treatment
|
||
| Completed |
NCT01406093 -
Early- and Late-onset Candidemia
|
N/A | |
| Completed |
NCT00670657 -
CRITIC - Treatment of Candidemia and Invasive Candidiasis
|
Phase 4 | |
| Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A | |
| Recruiting |
NCT04368559 -
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 3 |